Robert Azelby is CCO & VP at Juno Therapeutics, Inc. (JUNO). They have made 11 open-market trades across 2 companies since 2016, most recently 2026-06-19.
CIK 0001656998
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADCT | SELL | 2024-06-17 | 2024-06-18 | $2.89 | $20K | +38.3% | +38.0% | +15.8% |
| JUNO | SELL | 2018-02-12 | 2018-02-15 | $85.55 | $712K | +1.6% | N/A | N/A |
| JUNO | SELL · 10b5-1 | 2018-02-12 | 2018-02-14 | $85.55 | $356K | +0.9% | N/A | N/A |
| JUNO | SELL | 2018-02-08 | 2018-02-09 | $85.77 | $600K | +1.2% | N/A | N/A |
| JUNO | SELL | 2018-02-01 | 2018-02-02 | $85.78 | $715K | +0.3% | +1.7% | N/A |
| JUNO | SELL | 2018-01-22 | 2018-01-24 | $86.25 | $17.7M | -0.2% | +0.9% | N/A |
| JUNO | SELL | 2018-01-17 | 2018-01-19 | $68.61 | $4.0M | -0.5% | -1.5% | N/A |
| JUNO | SELL | 2017-12-18 | 2017-12-20 | $44.96 | $163K | +7.5% | +51.5% | N/A |
| JUNO | SELL | 2017-11-02 | 2017-11-03 | $54.95 | $733K | -3.2% | -6.2% | +46.9% |
| JUNO | SELL | 2017-09-13 | 2017-09-14 | $44.95 | $1.2M | -4.9% | -3.0% | +7.3% |
| JUNO | SELL | 2017-08-29 | 2017-08-31 | $39.95 | $1.0M | +9.5% | +10.6% | +31.7% |
| JUNO | SELL | 2016-11-10 | 2016-11-10 | $24.14 | $624K | -1.6% | -40.6% | -33.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.